1-methyl-1-isonicotinoylhydrazine | 89853-54-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-methyl-1-isonicotinoylhydrazine
• 英文别名: isonicotinic acid-(N-methyl-hydrazide)；Isonicotinsaeure-(N-methyl-hydrazid)；1-Isonicotinoyl-1-methyl-hydrazin；N-methylisonicotinic acid hydrazide；N-methylpyridine-4-carbohydrazide
• CAS: 89853-54-3
• 化学式: C₇H₉N₃O
• 分子量: 151.168
• InChiKey: ZPXUPNFFWCPHBL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-methyl-1-isonicotinoylhydrazine 在 P₂S₂ 、 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 氘代苯 、 N,N-二甲基甲酰胺 为溶剂， 生成 N'1,N'3-dimethyl-N'1,N'3-di(pyridine-4-carbonothioyl)malonohydrazide
  参考文献：
  名称：

  Syntheses and antitumor activities of N′1,N′3-dialkyl-N′1,N′3-di-(alkylcarbonothioyl) malonohydrazide: The discovery of elesclomol

  摘要：

  A series of N'(1),N'(3)-dialkyl-N'(1),N'(3)-di(alkylcarbonothioyl) malonohydrazides have been designed and synthesized as anticancer agents by targeting oxidative stress and Hsp70 induction. Structure-activity relationship (SAR) studies lead to the discovery of STA-4783 (elesclomol), a novel small molecule that has been evaluated in a number of clinical trials as an anticancer agent in combination with Taxol. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.07.032
• 作为产物：
  描述：

  N-methyl-N-isonicotinoylaminophthalimide 在 甲基肼 作用下， 以 四氢呋喃 为溶剂， 以40%的产率得到1-methyl-1-isonicotinoylhydrazine
  参考文献：
  名称：

  使用Mitsunobu协议通过N-酰基或N-烷氧基羰基氨基邻苯二甲酰亚胺的烷基化反应合成1,1取代的肼。

  摘要：

  N-酰基和N-烷氧基羰基氨基邻苯二甲酰亚胺使用方便的反应制备，并有效地用作Mitsunobu反应中的酸伙伴。该反应使它们被伯，仲或苄基烷基化。这些N-取代的氨基邻苯二甲酰亚胺的反应性和pK（a）值的比较表明，在这种情况下，Mitsunobu反应的成功似乎更多地取决于空间而不是电子效应。最终的脱邻苯二甲酰化步骤导致制备1，1-取代肼的有效方法。

  DOI：

  10.1021/jo000225s

文献信息

• Anti-hyperuricemia composition
  申请人：Merck & Co., Inc.

  公开号：US03947577A1

  公开（公告）日：1976-03-30

  Compositions useful in the treatment of gout and hyperuricemia and containing a substituted 1,2,4-triazole as the active ingredient are provided, the triazoles being substituted at the 5 position with a pyridyl radical and at the 3 position with a phenyl or a pyridyl radical. Methods of preparing these substituted triazoles are described. Certain of the compounds are novel.

  提供了一种用于治疗痛风和高尿酸血症的化合物，其活性成分为取代的1,2,4-三唑，其中三唑在5位被吡啶基取代，在3位被苯基或吡啶基取代。描述了制备这些取代三唑的方法。其中某些化合物是新颖的。
• Pyridyl containing 1-benzenesulfonyl triazoles
  申请人：Merck & Co., Inc.

  公开号：US03963731A1

  公开（公告）日：1976-06-15

  Compositions useful in the treatment of gout and hyperuricemia and containing a substituted 1,2,4-triazole as the active ingredient are provided, the triazoles being substituted at the 5 position with a pyridyl radical and at the 3 position with a phenyl or a pyridyl radical. Methods of preparing these substituted triazoles are described. Certain of the compounds are novel.

  本发明提供了一种用于治疗痛风和高尿酸血症的有效组合物，其中含有取代的1,2,4-三唑作为活性成分，该三唑在5位被吡啶基取代，在3位被苯基或吡啶基取代。本发明还描述了制备这些取代三唑的方法。其中某些化合物是新颖的。
• The chemotherapy of tuberculosis. Part VI. Some derivatives of isonicotinic acid
  作者：J. Cymerman-Craig、D. Willis

  DOI：10.1039/jr9550004315

  日期：——
• Synthetic Tuberculostats. XI. Trialkyl and Other Derivatives of Isonicotinylhydrazine
  作者：H. HERBERT FOX、J. T. GIBAS

  DOI：10.1021/jo01109a024

  日期：1956.3
• Multi-API Loading Prodrugs
  申请人：Zeidan Tarek A.

  公开号：US20120202823A1

  公开（公告）日：2012-08-09

  The present invention accomplishes this by having multiple molecules of parent drugs attached to carrier moieties and by extending the period during which the parent drug is released and absorbed after administration to the patient and providing a longer duration of action per dose than the parent drug itself. Prodrug conjugates are suitable for sustained delivery of heteroaryl, lactam- amide-, imide-, sulfonamide-, carbamate-, urea-, benzamide-, acylaniline-, cyclic amide- and tertiary amine-containing parent drugs that are substituted at the amide nitrogen or oxygen atom with labile aldehyde-linked prodrug moieties. The carrier groups of the prodrugs can be hydrophobic to reduce the polarity and solubility of the parent drug under physiological conditions.